Search research articles
Contact Us
Filters
Showing results (21-30 of 1,451) with videos related to
Page
of 146
Sort By:
The American Journal of Cardiology
|
May 4, 2020
Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation
Lanting Yang, Maria M Brooks, Nancy W Glynn, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
April 24, 2024
Projected prescription drug expenditures in 2024: Looking ahead to the inflation reduction era
Inmaculada Hernandez
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
June 13, 2015
Time to reconsider dabigatran 110 mg in the USA
Inmaculada Hernandez
JAMA Internal Medicine
|
August 8, 2017
Revisiting Outcomes-Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab
Inmaculada Hernandez
Journal of Managed Care & Specialty Pharmacy
|
December 28, 2023
A primer on brand-name prescription drug reimbursement in the United States
Inmaculada Hernandez, Anna Hung
Journal of Managed Care & Specialty Pharmacy
|
February 25, 2023
Drugs likely subject to Medicare negotiation, 2026-2028
Sean Dickson, Inmaculada Hernandez
JAMA Internal Medicine
|
June 6, 2018
Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine
Chester B Good, Inmaculada Hernandez
JAMA
|
October 18, 2022
Pharmaceutical Spending in Fee-for-Service Medicare: Looking Ahead to the Inflation Reduction Act
Walid F Gellad, Inmaculada Hernandez
JAMA Health Forum
|
October 11, 2022
Decomposition of Expenditures for Insulins Across the Distribution Chain-Insights Into Rising Prices?
Chester B Good, Inmaculada Hernandez
Obesity (Silver Spring, Md.)
|
January 16, 2024
Net prices of new antiobesity medications
Inmaculada Hernandez, Sean D Sullivan
Page
of 146
Search research articles
Search
Showing results (21-30 of 1,451) with videos related to
Sort By:
Page
of 146
The American Journal of Cardiology
|
May 4, 2020
Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation
Lanting Yang, Maria M Brooks, Nancy W Glynn, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
April 24, 2024
Projected prescription drug expenditures in 2024: Looking ahead to the inflation reduction era
Inmaculada Hernandez
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
June 13, 2015
Time to reconsider dabigatran 110 mg in the USA
Inmaculada Hernandez
JAMA Internal Medicine
|
August 8, 2017
Revisiting Outcomes-Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab
Inmaculada Hernandez
Journal of Managed Care & Specialty Pharmacy
|
December 28, 2023
A primer on brand-name prescription drug reimbursement in the United States
Inmaculada Hernandez, Anna Hung
Journal of Managed Care & Specialty Pharmacy
|
February 25, 2023
Drugs likely subject to Medicare negotiation, 2026-2028
Sean Dickson, Inmaculada Hernandez
JAMA Internal Medicine
|
June 6, 2018
Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine
Chester B Good, Inmaculada Hernandez
JAMA
|
October 18, 2022
Pharmaceutical Spending in Fee-for-Service Medicare: Looking Ahead to the Inflation Reduction Act
Walid F Gellad, Inmaculada Hernandez
JAMA Health Forum
|
October 11, 2022
Decomposition of Expenditures for Insulins Across the Distribution Chain-Insights Into Rising Prices?
Chester B Good, Inmaculada Hernandez
Obesity (Silver Spring, Md.)
|
January 16, 2024
Net prices of new antiobesity medications
Inmaculada Hernandez, Sean D Sullivan
Page
of 146